Liquid Encapsulation Utilizing An Emulsion Or Dispersion To Form A Solid-walled Microcapsule (includes Liposome) Patents (Class 264/4.1)
  • Patent number: 11110061
    Abstract: The present invention relates to a biodegradable polymer microsphere-containing sustained-release injection containing escitalopram as an active ingredient, and to a method for manufacturing the same. In the case of escitalopram microspheres, there is a problem of low encapsulation rate, fracture due to weak strength, and initial over-release due to the phase separation of the liquid drug and the polymer inside the microspheres. In order to solve the problem, it is possible to maximize the encapsulation amount and the encapsulation efficiency of the escitalopram adding a hydrophobic solidifying agent to uniformize the non-uniform phase, to overcome the cracking of the microspheres at high loading conditions, and to properly control the initial release and release delay of the microspheres.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: September 7, 2021
    Inventors: Byung Chul Shin, Sun Hang Cho, Tae Kyung Yang, Seok Hee Kang, Eun Hee Park
  • Patent number: 11111300
    Abstract: The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: September 7, 2021
    Assignee: APOLLOMICS INC.
    Inventors: Jiping Zha, Ziyong Sun, Junzhuan Qiu
  • Patent number: 11103486
    Abstract: The present invention provides novel methods for treating Th2-mediated immune disorders and enhancing Th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (SGK1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught. The present invention also provides methods for augmenting the treatment of subjects having viral or parasitic infections, or which have cancerous tumors.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: August 31, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan David Powell, Emily Beth Heikamp
  • Patent number: 11103523
    Abstract: The invention provides amphiphilic liquid crystalline brush block copolymers that can readily self-assemble to nanoparticles in aqueous solutions and also allow for encapsulation of hydrophobic pharmaceutically active molecules.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: August 31, 2021
    Assignee: University of Connecticut
    Inventors: Xiuling Lu, Rajeswari Kasi, Thanh-Huyen Tran, Chi Thanh Nguyen, Prashant Deshmukh
  • Patent number: 11096898
    Abstract: A membrane including a barrier having layers of alginate with different material molar concentrations relative to another material. The layers have a uniform consistency across a thickness of the layers. The thickness is free of laminae and interfaces and forms a single layer morphology that provides permeability for selected molecules.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: August 24, 2021
    Assignee: GH CARE INC.
    Inventors: Giuseppe Pietro Pio Basta, Pia Montanucci, Riccardo Calafiore
  • Patent number: 11091523
    Abstract: Recombinant transforming growth factor (TGF)-? monomers modified to inhibit dimerization and block TGF-? signaling are described. The recombinant TGF-? monomers lack the ability to bind and recruit TGF-? type I receptor (T?RI), but retain the capacity to bind the high affinity TGF-? type II receptor (T?RII), and in some instances, include mutations that increase their affinity for T?RII. Nucleic acid molecules and vectors encoding the recombinant TGF-? monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-? monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-? monomers and/or cells producing the recombinant TGF-? monomers, to inhibit TGF-? signaling, such as to treat disorders associated with aberrant TGF-? signaling, are also described.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 17, 2021
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Research Council of Canada
    Inventors: Andrew Peterson Hinck, Traian Sulea
  • Patent number: 11083693
    Abstract: The present invention is directed to a liposomal formulation comprising a lipid ingredient encapsulating vilanterol trifenatate, and a method for administering the liposomal formulation by nebulizing the liposomal formulation in an inhaler. The liposomal formulation comprises vilanterol or a salt thereof, and lipid ingredients comprising a pharmaceutical lipid and/or a sterol. The drug to lipid mass ratio is in the range of about 1:20 to about 1:100. Additionally, the present invention is directed to the use of the liposomal formulation for the prevention or treatment of respiratory diseases such as Chronic Obstructive Pulmonary Disease and/or asthma.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: August 10, 2021
    Inventors: Cai Gu Huang, Xiao Ting Huang
  • Patent number: 11073520
    Abstract: Embodiments described herein include detecting an analyte in a low pH sample. Some embodiments include detection of multiple analytes in a sample utilizing a plurality of analyte binders and a control zone containing multiple control zone capture agents. In some embodiments, the multiple control zone capture agents capture a plurality of binders within one control zone.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 27, 2021
    Assignee: Charm Sciences, Inc.
    Inventors: Robert J. Markovsky, David W. Douglas
  • Patent number: 11052046
    Abstract: Methods for preparing micro-particles using a double emulsion technique combining a membrane and a micro-sieve are provided. Particularly the present invention relates to method for preparing micro-particles comprising: preparing a first phase comprising an active agent; preparing a second phase comprising a carrier and a solvent; passing the first phase and the second phase through a membrane to form a primary emulsion; passing the primary emulsion through a micro-sieve in a continuous phase to form a secondary emulsion; and removing the solvent to form the micro-particles.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: July 6, 2021
    Assignee: NANOMI B.V.
    Inventors: Emilie Janine Marie Blazejewski, Robertus Franciscus Duwel
  • Patent number: 11046752
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 29, 2021
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
  • Patent number: 11033495
    Abstract: Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: June 15, 2021
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Paige N. Davis, Louie D. Garcia, Stephanie M. Kurz, Kathleen D. A. Los
  • Patent number: 11035740
    Abstract: A stimulus indicating device is disclosed. The stimulus indicating device includes a stimulus sensitive amphiphilic gel; and an assembly having a first end and a second end. The assembly may include a top layer, a middle layer comprised of a porous polymer membrane, and a bottom layer. The top layer and the bottom layer may be sealed together on opposing sides of the assembly, and the top layer and the bottom layer may be sealed at the width of the second end of the assembly.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: June 15, 2021
    Assignee: Prasidiux, LLC
    Inventors: Joseph C. White, Bani H. Cipriano, Kevin K. Diehn, Rel S. Ambrozy
  • Patent number: 11021526
    Abstract: The invention provides Dsg2-derived peptides for inhibiting EMT and/or vasculogenic mimicry and treating and/or preventing angiogenesis-related diseases. Also provided are pharmaceutical compositions comprising the peptide of the invention and methods of using the peptide of the invention in inhibiting EMT and/or vasculogenic mimicry, and treating and/or preventing angiogenesis-related diseases.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 1, 2021
    Assignee: Asclepiumm Taiwan Co., Ltd
    Inventors: Min-che Chen, Chun-wei Chen
  • Patent number: 11001541
    Abstract: The present invention relates to methods of preparing purified cyclopropylene (1-methylcyclopropylene) gas employing one or more non-reactive purification processes to purify substances including, without limitation, cyclopropene (1-methylcyclopropylene) gas and/or lithio-cyclopropene.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: May 11, 2021
    Inventor: Nazir Mir
  • Patent number: 10987308
    Abstract: Disclosed are targeted sub-50 nanometer nanoparticles suitable for delivering bioactive agents of interest, and related compositions, methods, and systems, which improve the manufacturing, stability, efficacy and other aspects of therapeutic nanoparticles.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: April 27, 2021
    Assignee: GENESEGUES, INC.
    Inventor: Gretchen M. Unger
  • Patent number: 10988633
    Abstract: The invention aims to provide a novel compound to be suitably used for antifouling agents. The compound of the invention is represented by the following formula (1): wherein R1 is a monovalent organic group containing a polyether chain; X1 and X2 are each individually a monovalent group; and the polyether chain is a chain represented by the following formula: —(OC6F12)m11—(OC5F10)m12—(OC4F8)m13—(OC3X106)m14—(OC2F4)m15—(OCF2)m16—, wherein m11, m12, m13, m14, m15, and m16 are each individually an integer of 0 or 1 or greater; X10s are each individually H, F, or Cl; and the repeating units are present in any order.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: April 27, 2021
    Assignee: DAIKIN INDUSTRIES, LTD.
    Inventors: Tsuneo Yamashita, Masatoshi Nose, Hisashi Mitsuhashi, Saya Nii, Eiji Sakamoto, Kaori Ozawa
  • Patent number: 10981994
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof that bind to PD-1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-1 antibodies and methods of use thereof.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: April 20, 2021
    Assignee: Apollomics Inc.
    Inventors: Junzhuan Qiu, Ziyong Sun, Jiping Zha
  • Patent number: 10968271
    Abstract: The present invention relates to amino acid sequences that are directed against Interleukin-23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODIES® against IL-23 and one NANOBODY® against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: April 6, 2021
    Assignee: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • Patent number: 10947303
    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 16, 2021
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.
    Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
  • Patent number: 10941057
    Abstract: A particle for emulating pollutant tracking in water has a florescent core. A semitransparent shell is formed around the florescent core.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: March 9, 2021
    Assignee: U.S. Environmental Protection Agency
    Inventor: Anthony Todd Zimmer
  • Patent number: 10913882
    Abstract: The method for low temperature microencapsulation of phase change materials or other components includes the following steps: (a) preparing a phase change emulsion including droplets of at least one active phase-change material in water with a surfactant; (b) adding a monomer of at least one encapsulating agent; (c) introducing the phase change emulsion into a UV reactor while stirring the emulsion; and (d) initiating the photo polymerization of monomers using at least one UV lamp inside the UV reactor for photo polymerization until the phase change material is encapsulated within a polymeric shell to form microcapsules. The microcapsules obtained by this process may have a diameter between about 0.5 to about 2 ?m. Other sizes can also be obtained by changing stirring speed of the emulsion.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: February 9, 2021
    Assignees: QATAR UNIVERSITY, COLLEGE OF THE NORTH ATLANTIC-QATAR, AUCKLAND UNISERVICES LIMITED
    Inventors: Mohammed Farid, Refat Al Shannaq, Shaheen Al-Muhtaseb, Jamal Kurdi
  • Patent number: 10898435
    Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: January 26, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
  • Patent number: 10881100
    Abstract: An aqueous suspoemulsion, characterized in that it contains at least the two components: (a) a dispersed oil phase comprising: (i) lambda-cyhalothrin as the first active ingredient, and (ii) at least one C9-C10 aromatic hydrocarbon solvent having lambda-cyhalothrin dissolved therein; (b) a continuous water phase containing: (i) at least one water-insoluble second active ingredient which is suspended in the continuous phase; and (ii) a dispersing agent in an amount sufficient to disperse the water-insoluble active ingredient. Methods of making and using this suspoemulsion are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: January 5, 2021
    Assignee: ROTAM AGROCHEM INTERNATIONAL COMPANY LIMITED CHAI WAN
    Inventor: James Timothy Bristow
  • Patent number: 10870690
    Abstract: The present invention relates to compositions for treating cancer by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: December 22, 2020
    Inventor: Yihong Zhou
  • Patent number: 10857080
    Abstract: Lipid microcapsules are described that can include at least one lipophilic active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions including the same and a method for the production thereof. Methods of using such a composition to treat dermatological pathologies are also described.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: December 8, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Mallard, Carole Dubayle
  • Patent number: 10842721
    Abstract: Purified polyurea capsules that encapsulate active materials for use in personal care, fine fragrance, or deodorant products are provided as are methods for producing the same.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: November 24, 2020
    Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Yabin Lei, Li Xu, Carol Joyce, Lewis Michael Popplewell
  • Patent number: 10835606
    Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)”—S—Bi2Hii2? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: November 17, 2020
    Assignee: Tenboron Oy
    Inventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
  • Patent number: 10835577
    Abstract: The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 17, 2020
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Chandramouli Chillakuri, Dhaval Sangani, Graham Hood, Alina Popa
  • Patent number: 10824822
    Abstract: A method, system, and mobile terminal configured for medication management are provided. A read operation is performed by a magnetic reader to detect whether a pattern of bio-compatible nano-magnetic particles on a pill is present within a body of a patient. Information from the read operation is transmitted to a mobile terminal by the wireless transceiver.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: November 3, 2020
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Rajeev Narayanan, Bing Dang, Bo Wen
  • Patent number: 10807060
    Abstract: A method for preparing solid microcapsules, comprising the steps of adding under agitation a composition C1 comprising at least one active material to a cross-linkable liquid composition C2, the active material is not an additive to be used in the lubricant, fuel or bitumen industries, drilling sludges or muds, or oil exploration/production, compositions C1 and C2 being immiscible with each other. A first emulsion is obtained comprising droplets of composition C1 dispersed in composition C2, adding under agitation the first emulsion to a liquid composition C3, composition C3 and composition C2 being immiscible with each other, to obtain a second emulsion comprising droplets dispersed in composition C3.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: October 20, 2020
    Assignee: CALYXIA
    Inventors: Jamie Walters, Damien Demoulin, Jérôme Bibette
  • Patent number: 10799619
    Abstract: Hydrogels and composite material containing hydrogels and liposomes dispersed therein, which exhibit a reduced friction coefficient compared to neat hydrogels or composites containing hydrogels, processes for preparing the same, and methods for using the same are disclosed.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: October 13, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Jacob Klein, Ronit Goldberg, Noa Iuster, Raya Sorkin
  • Patent number: 10799461
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: October 13, 2020
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTD
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10772807
    Abstract: Lipid microcapsules are described that can include at least one irritant active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions comprising the same, and methods for the production thereof. A method of using the composition to treat dermatological pathologies is also described.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: September 15, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Mallard, Carole Dubayle
  • Patent number: 10759832
    Abstract: Peptides having a human minute binding protein-2 (HDM-2) targeting sequence that target the human minute binding protein-2, fusion proteins having a HDM-2 targeting sequence, and methods of using the peptides and proteins to treat cancer are described.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: September 1, 2020
    Assignee: SLH Innovations LLC
    Inventor: Matthew R. Pincus
  • Patent number: 10759843
    Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 1, 2020
    Inventors: Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
  • Patent number: 10736845
    Abstract: A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: August 11, 2020
    Assignee: Cureport Inc.
    Inventors: De-Min Zhu, Guoqiang Chen
  • Patent number: 10729748
    Abstract: Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 90% of the hemoglobin in the composition is provided in CO-charged form.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: August 4, 2020
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventor: Michael Sander
  • Patent number: 10723780
    Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 28, 2020
    Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
  • Patent number: 10723765
    Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Xaa1-Xaa2-Thr3-Xaa4-Ser5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-) and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa4, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 and Xaa13 being amino acid residues which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: July 28, 2020
    Assignee: POLYPHOR AG
    Inventors: Frank Otto Gombert, Daniel Obrecht, Odile Sellier-Kessler
  • Patent number: 10716774
    Abstract: Isotretinoin compositions having improved bioavailability are disclosed. The compositions are oral formulations containing isotretinoin, a lipid excipient and a cosolvent, wherein the ratio of isotretinoin to the lipid excipient is from about 1:1.2 to about 1:1.6. The compositions can be in the form of a pharmaceutically acceptable oral dosage form such as a capsule or compressed tablet wherein the isotretinoin is adsorbed onto blended particles of a cellulosic polymer and silicon dioxide in combination with a lipid excipient such as soy phosphatidylcholine and a cosolvent such as propylene glycol. Methods of preparing the compositions and methods of treatment using the compositions are also disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 21, 2020
    Assignee: YALE PHARMACEUTICALS LLC
    Inventor: Basavaraj Siddalingappa
  • Patent number: 10687541
    Abstract: Coconut oil, coconut oil blends that are high in MCTs such as LouAna® liquid coconut oil, pure MCT oils, and Omega-3 oils may be emulsified to create an emulsified oil or blend that may take the form of a creamy shot or a cream substitute. These oils and/or blends may be emulsified using an emulsifier that may be selected from the following: sunflower lecithin, sodium stearoyl lactylate (SSL), or a combination of sunflower lecithin and SSL. By emulsifying these oils/oil blends, a good tasting creamy shot or a cream substitute can be formed.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 23, 2020
    Inventor: Jesse Windrix
  • Patent number: 10653735
    Abstract: Use of Mesembryanthemum crystallinum L. callus extract in the manufacture of a medicament or a skin care product, wherein the medicament or skin care product is for at least one of delaying skin cell aging, nursing skin, repairing skin, treating skin cancer, and preventing skin cancer.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: May 19, 2020
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Wei-Wen Kuo, I-Hui Chen, Yi-Chun Chen, Hui-Hsin Shih, Yun-Ching Tsai
  • Patent number: 10653786
    Abstract: Provided herein relates to compositions and methods for lubrication of a surface. The surface amenable to the compositions and methods described herein can be a non-biological surface, a biological surface, or a combination thereof. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for lubrication of a surface. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for joint lubrication, e.g., for treatment of joint disorders such as arthritis.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 19, 2020
    Assignees: TRUSTEES OF TUFTS COLLEGE, Tulane Educational Fund
    Inventors: David L. Kaplan, Xiaoqin Wang, Vijay John, Noshir Pesika, Rubo Zheng
  • Patent number: 10640565
    Abstract: The present invention provides novel humanized anti-human C-C chemokine receptor type 7 (CCR7) antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: May 5, 2020
    Assignee: PepMab B.V.
    Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
  • Patent number: 10639348
    Abstract: The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 5, 2020
    Assignee: IDP DISCOVERY PHARMA, S.L.
    Inventors: Santiago Esteban Martín, Laura Nevola
  • Patent number: 10617128
    Abstract: Coconut oil, coconut oil blends that are high in MCTs such as LouAna® liquid coconut oil, pure MCT oils, Omega-3oils, cannabidiol (CBD), hemp extract, tree nut oil, macadamia oil, almond oil, cashew oil, avocado oil, docosahexaenoic acid (DHA), fish oil, and/or conjugated linoleic acid (CLA) may be emulsified to create an emulsified oil or blend that may take the form of a creamy shot or a cream substitute. These oils and/or blends may be emulsified using an emulsifier that may be selected from the following: sunflower lecithin, sodium stearoyl lactylate (SSL), acacia gum, beta-cyclodextrin, and combinations of same. By emulsifying these oils/oil blends, a good tasting creamy shot or a cream substitute can be formed.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: April 14, 2020
    Inventor: Jesse Windrix
  • Patent number: 10611797
    Abstract: A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: April 7, 2020
    Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Chul Geun Kim, Min Young Kim, Chan Gil Kim, Ho Chul Kang, Ji Hyung Chae, Su Jae Lee, Eun Jung Baek, Chae Ok Yun, Jin Won Lee, Young Su Lim, Je Min Choi, Dae Hyun Ha, Hyung Sik Won, Seung Han Son
  • Patent number: 10548841
    Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: February 4, 2020
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Arturo Santos, Phillip Frost
  • Patent number: 10543274
    Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 28, 2020
    Assignee: ONCOPEPTIDES AB
    Inventors: Jack Spira, Fredrik Lehmann
  • Patent number: 10537623
    Abstract: Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). Further, an in vitro method for preparing an antigen-presenting cell is provided. The method includes the step of contacting the antigen-presenting cell with the at least one polypeptide selected from: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a).
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: January 21, 2020
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Akira Kurihara, Fumiyoshi Okano